Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: β-catenin drives resistance to PI3K and AKT inhibitors and promotes colon cancer metastasis by disrupting FOXO3a function

  • By

  • Stephan P. Tenbaum

  • Paloma Ordóñez-Morán

  • Isabel Puig

  • Irene Chicote

  • Oriol Arqués

  • Stefania Landolfi

  • Yolanda Fernández

  • José Raúl Herance

  • Juan D. Gispert

  • Leire Mendizabal

  • Susana Aguilar

  • Santiago Ramón y. Cajal

  • Simó Schwartz

  • Ana Vivancos

  • Eloy Espín

  • Santiago Rojas

  • José Baselga

  • Josep Tabernero

  • Alberto Muñoz

  • Héctor G. Palmer

  • October 22, 2026

Share

  • 1

    The correction concerns a Nature Medicine report with DOI 10.1038/nm.2772, published online May 20, 2012.

  • 2

    The original article’s Fig. 6b contained a duplicated image in the “T49, Xenograft” panel.

  • 3

    The duplicated image in Fig. 6b had been taken from Fig. 1b.

  • 4

    The corrected Fig. 6b replaces the “T49, Xenograft” panel with a different representative confocal image.

  • 5

    The replacement image corresponds to the staining described for that panel.

Original Source(s)

Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

  • by Stephan P. Tenbaum, Paloma Ordóñez-Morán, Isabel Puig, Irene Chicote, Oriol Arqués, Stefania Landolfi, Yolanda Fernández, José Raúl Herance, Juan D. Gispert, Leire Mendizabal, Susana Aguilar, Santiago Ramón y. Cajal, Simó Schwartz, Ana Vivancos, Eloy Espín, Santiago Rojas, José Baselga, Josep Tabernero, Alberto Muñoz, Héctor G. Palmer

  • October 22, 2026

Related Content

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

  • October 15, 2026

  • 1 min
2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

  • October 15, 2026

  • 1 min